Relative Strength Chart Kymera Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX Other stock markets 15:39:48 18/06/2026 BST			5-day change	1st Jan Change
90.52 ^USD	+0.70%		+9.76%	+17.03%

06-12	Kymera Says KT-621 Data in Japanese Adults Comparable With Previous Studies	MT
06-12	Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for Kt-621, A First-In-Class Oral Stat6 Degrader, At the Japanese Dermatological Association Annual Meeting	CI